Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

United Therapeutics (UTHR) Short-term Investments (2016 - 2025)

Historic Short-term Investments for United Therapeutics (UTHR) over the last 17 years, with Q3 2025 value amounting to $1.4 billion.

  • United Therapeutics' Short-term Investments fell 1946.86% to $1.4 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.4 billion, marking a year-over-year decrease of 1946.86%. This contributed to the annual value of $1.6 billion for FY2024, which is 1212.49% down from last year.
  • United Therapeutics' Short-term Investments amounted to $1.4 billion in Q3 2025, which was down 1946.86% from $1.5 billion recorded in Q2 2025.
  • United Therapeutics' 5-year Short-term Investments high stood at $1.9 billion for Q4 2022, and its period low was $899.0 million during Q1 2021.
  • Moreover, its 5-year median value for Short-term Investments was $1.5 billion (2022), whereas its average is $1.5 billion.
  • As far as peak fluctuations go, United Therapeutics' Short-term Investments surged by 8124.34% in 2022, and later crashed by 1946.86% in 2025.
  • Quarter analysis of 5 years shows United Therapeutics' Short-term Investments stood at $1.0 billion in 2021, then surged by 81.24% to $1.9 billion in 2022, then fell by 4.85% to $1.8 billion in 2023, then dropped by 12.12% to $1.6 billion in 2024, then decreased by 9.06% to $1.4 billion in 2025.
  • Its last three reported values are $1.4 billion in Q3 2025, $1.5 billion for Q2 2025, and $1.4 billion during Q1 2025.